Core Viewpoint - Tongrentang Technology has successfully launched its key cardiovascular drug, the Kuanxiong Aerosol, which has entered the production phase, reflecting the company's commitment to innovation in modern pharmaceutical technology [1][4]. Group 1: Product Development - The Kuanxiong Aerosol is developed based on traditional Chinese medicine theories, targeting the root causes of cardiovascular diseases such as coronary heart disease and angina [3]. - The aerosol employs an innovative sublingual spray delivery method, allowing active ingredients to be rapidly absorbed into the bloodstream, enhancing the drug's efficacy [4]. - The production process incorporates advanced technology to improve drug stability and minimize the degradation of active components, ensuring consistent therapeutic effects [4]. Group 2: Market Position and Future Plans - Tongrentang Technology currently offers over 20 types of cardiovascular medications, including Guanxin Suhe Pills and Compound Danshen Tablets, focusing on the growing demand for cardiovascular treatments [4]. - The company is accelerating the development of its innovative traditional Chinese medicine, Qishen Granules, aimed at treating chronic heart failure, which has successfully completed Phase II clinical trials [4].